Received Oct 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | 1957404 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 4 | Y009051 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | Y009051 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | 1957404 | — |
No adverse event; HCP reports that the patient received an extra dose of GARDASIL 9 and the third and fourth doses were administered prior to the minimal interval that is outlined. Please see patients dosing schedule below for background. No additional information wa; HCP reports that the patient received an extra dose of GARDASIL 9 and the third and fourth doses were administered prior to the minimal interval that is outlined. Please see patients dosing schedule below for background. No additional information wa; This spontaneous report was received from an Other health professional and refers to a 33-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 17-Sep-2023, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Injection (lot #1957404, expiration date: 05-Oct-2025), dose number 1, 0.5 mL (0.5ml/ series dose 1) for prophylaxis. On 14-Sep-2024, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Injection (lot #1957404, expiration date: 05-Oct-2025), dose number 2, 0.5 mL (dose 2) for prophylaxis. On 25-Nov-2024, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Injection (lot #Y009051, expiration date: 08-Oct-2026), dose number 3, 0.5 mL (dose 3) for prophylaxis (Inappropriate schedule of product administration). On 22-Jan-2025, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Injection (lot #Y009051, expiration date: 08-Oct-2026), dose number 4, 0.5 mL (dose 4) for prophylaxis (Extra dose administered). It was reported that the patient received an extra dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) and the third and fourth doses were administered prior to the minimal interval that was outlined. No additional information was provided. There was no additional adverse event (No adverse event).